Compugen (CGEN) announced that it is entitled to receive a $10M milestone payment from AstraZeneca (AZN) after the first patient was dosed in AstraZeneca’s ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical-stage anti-TIGIT antibody, COM902. The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CGEN:
- Biotech Alert: Searches spiking for these stocks today
- Compugen spikes after deal with Gilead for anti-tumor drug
- Compugen spikes 180% on $848M deal with Gilead for anti-tumor drug
- Compugen eligible to receive $10M payment upon dosing of AstraZeneca trial
- Gilead and Compugen in license deal for novel pre-clinical immunotherapy program
